The 11 most innovative medical devices of 2017


7. Integra LifeSciences: Omnigraft dermal regeneration matrix


[Image from Omnigraft]

The Omnigraft dermal regeneration matrix from Integra Lifesciences is an advanced bilayer dermal regeneration matrix that treats diabetic foot ulcers. It is the only FDA-approved product that can regenerate native dermal tissue, according to the company. The patch has a built-in silicone layer that serves as a temporary epidermal layer and provides immediate coverage for wound protection. It can be removed between two and three weeks. Under the silicone layer is a collagen/chrondroitin-6-sulfate matrix that acts as a dermal replacement layer. It is a bioengineered scaffold that promotes dermal regeneration and is designed with a controlled porosity and degradation rate.The Omnigraft dermal regeneration matrix is designed to be used for treating partial and full thickness neuropathic diabetic foot ulcers that are more than six weeks old with no capsule, tendon or bone showing.

Next >>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12

Speak Your Mind